Marbofloxacin is a broad-spectrum fluoroquinolone antibiotic active against both Gram-negative and Gram-positive bacteria. It is believed to act by impairing the bacterial DNA gyrase. Marbofloxacin has also been shown to exhibit antileishmanial activity in a canine model.
Legal Information
Zeniquin is a registered trademark of Pfizer, Inc.
Mycoplasma haemofelis is the most pathogenic feline hemoplasma species and a causative agent of infectious hemolytic anemia in cats. Current treatment protocols are effective in reducing M. haemofelis blood loads and clinical signs but consistent bacteremia clearance is rarely achieved.
Journal of veterinary pharmacology and therapeutics, 18(4), 284-289 (1995-08-01)
Marbofloxacin is a new fluoroquinolone developed exclusively for veterinary use. Minimum inhibitory concentrations of marbofloxacin were assessed for 816 recent isolates associated with canine or feline diseases. Marbofloxacin showed a broad spectrum of activity against gram-negative and gram-positive bacteria. In
Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
